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Methamphetamine (METH) is a highly addictive psychostimulant that not only affects the
brain and cognitive functions but also greatly impacts the host immune system, rendering
the body susceptible to infections and exacerbating the severity of disease. Although
there is gathering evidence about METH abuse and increased incidence of HIV and other
viral infections, not much is known about the effects on the immune system in a chronic
viral infection setting. We have used the lymphocytic choriomeningitis virus (LCMV)
chronic mouse model of viral infection in a chronic METH environment and demonstrate
that METH significantly increases CD3 marker on splenocytes and programmed death-1
(PD-1) expression on T cells, a cell surface signaling molecule known to inhibit T cell
function and cause exhaustion in a lymphoid organ. Many of these METH effects
were more pronounced during early stage of infection, which are gradually attenuated
during later stages of infection. An essential cytokine for T-lymphocyte homeostasis,
Interleukin-2 (IL-2) in serum was prominently reduced in METH-exposed infected mice.
In addition, the serum pro-inflammatory (TNF, IL12 p70, IL1β, IL-6, and KC-GRO) and
Th2 (IL-2, IL-10, and IL-4) cytokine profiles were also altered in the presence of METH.
Interestingly CXCR3, an inflammatory chemokine receptor, showed significant increase
in the METH treated LCMV infected mice. Similarly, compared to only infected mice,
epidermal growth factor receptor (EGFR) in METH exposed LCMV infected mice were up
regulated. Collectively, our data suggest that METH alters systemic, peripheral immune
responses and modulates key markers on T cells involved in pathogenesis of chronic
viral infection.
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Introduction
Methamphetamine (METH) is an extremely addictive central nervous system (CNS) stimulant.
Recreational METH use is one of the fastest growing substance abuse problems in the United States
(Cruickshank and Dyer, 2009). METH is self-administered intravenously, by nasal inhalation,
anally, and orally, in doses of 250–500mg by occasional users to as much as 1 g by chronic
abusers (Tallóczy et al., 2008). Although there is substantial evidence of the effects of METH on
CNS functions (Loftis and Janowsky, 2014), the effects of METH on systemic immune responses
has not been extensively described. Few studies that have addressed this demonstrated that
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METH suppresses both innate and adaptive immunity in animals
and humans (Yu et al., 2002; Martinez et al., 2009; Harms et al.,
2012). These and other studies reveal that METH profoundly
interferes with immunological networks and affects diverse
leukocyte subsets, thereby increasing susceptibility to infection
(Ellis et al., 2003; Martinez et al., 2009). In vitro use of
amphetamines, including METH, affects immune function with
a significant suppression of IL-2 (Potula et al., 2010), but not
IL-4 production by T-lymphocytes, as well as a suppression of
B-lymphocyte proliferation; however, this occurred only at the
highest amphetamine concentrations (Steinkellner et al., 2011;
Kwack et al., 2014).
Considerable evidence exists linking drug abuse to immune
dysregulation and enhanced susceptibility to the progression of
chronic infections, such as HIV-1(Ellis et al., 2003; Mantri et al.,
2014). METH use is associated with high-risk sexual behavior
and high rates of HIV acquisition and progression (Jamieson
et al., 1997; Ellis et al., 2003). In this report, we have used
the mouse model of chronic lymphocytic choriomeningitis virus
(LCMV) infection to study the effects ofMETH on T cell immune
responses. Although LCMV is a relatively simple virus, encoding
only four gene products, it has proven to be one of the best
experimental systems for analyzing cellular immune responses
(Zhou et al., 2012). Several studies have reported that acute
infections induce remarkably high levels of antiviral T cells,
while protracted or chronic infections are associated with both
functional impairment and deletion of virus-specific CD8 T cells
(Khanolkar et al., 2002). T cell exhaustion has a major role
in failure to control chronic infection. Expression of inhibitory
receptors, including PD-1, an inhibitory receptor of the CD28–
CTLA-4 family are up regulated considerably in chronic viral
infection (Barber et al., 2006). This along with the inability to
sustain functional T cell responses contribute to exhaustion. CD4
Th cells are central orchestrators of the immune response and
differentially activate diverse branches of innate and adaptive
immunity to guide the appropriate response to an invading
pathogen (Penaloza-MacMaster et al., 2014). CD4 Th1 immunity
is critical to sustain residual CD8 T-cell activity to control
infection during persistent infection and is characterized in CD4
T cells by the secretion of IFN-γ, TNF-α, and IL-2 (Matloubian
et al., 1994).
So far no study has addressed the role of METH in the context
of chronic viral infection to analyze the effects on T cell immune
responses. In this report, we have systematically analyzed the
classic responses of CD4 and CD8 T cells in secondary lymphoid
organ namely spleen during chronic LCMV infection in mice
that have been exposed to chronic METH and the peripheral
responses by measuring the serum cytokines.
Our findings indicate that METH administered in a s.c. route
altered T cells responses with important consequences, in a
chronic LCMV infection model. METH effects on CD4 and CD8
cell percentages per se were modest although the expression of
important markers of LCMV infection and T cell exhaustion
such as PD-1 was greatly increased. Many of the METH effects
were more pronounced by day 14 but normalized as infection
progressed up to 56 days. Serum cytokine analysis revealed
reduction of IL-2 production at all time points inMETH-exposed
infected mice than without. The serum pro-inflammatory (TNF,
IL12p70, IL1β, IL-6, and KC-GRO) and Th2 (IL-2, IL-10,
and IL-4) cytokine profiles were also altered in the presence
of METH. Interestingly CXCR3, an inflammatory chemokine
receptor, showed significant increase in theMETH treated LCMV
infected mice, suggesting that METH modulates the migratory
properties of T cells during infection thus affecting immune
activation. We also found another interesting up regulation of
epidermal growth factor receptor (EGFR) in METH exposed
LCMV infected mice at later times of infection, suggesting
that signaling through EGFR may enable to establish persistent
infection.
Materials and Methods
Mice
Male C57BL/6 mice 4 weeks of age were purchased from Jackson
Labs, housed in specific pathogen free conditions, and given
unlimited access to food and water. Protocols for the use of
animals were in accordance with the guidelines of and were
approved by the Institutional Animal Care and Use Committees
of Temple University, which is American Association for the
Accreditation of Laboratory Animal Care accredited facility.
METH Treatment and LCMV Infection
Methamphamphetamine Hydrochloride was purchased from
Sigma-Aldrich (St. Louis, MO). Mice were weight-matched and
randomly divided into groups and were administered a gradual
escalating METH dose from 0.45–10mg/kg over 6 days, followed
by a single dose of 10mg/kg/day subcutaneously (s.c. at the
nape of the neck) until the mice were sacrificed. Once daily
injection of METH was established, mice were intravenously
injected with LCMV Clone 13 (2 × 106 pfu). Experimental
scheme is shown in Figure 1A. Peripheral blood was collected
via submandibular vein into EDTA coated collection tubes (BD
Biosciences) every 7 days until the end of the experiment. METH
levels in plasma were assayed using a sensitive Elisa kit from
Abnova (Taipei City, Taiwan). To determine the steady-state
levels of METH upon daily injection, mice were bled at the same
time at every time-point, to eliminate bias in the half-life of
METH. Blood was collected after 2 h of METH injection at each
time-point.
Quantitation of Viral Load
LCMV viral RNA was extracted from harvested and cleared
plasma, lung and spleen samples using Viral RNA extraction
kit (Qiagen). Extracted RNA was cleared of any genomic
DNA contamination using the DNA-free kit (Ambion).
Complimentary DNA was then generated using Superscript III
Reverse Transcriptase (Life Sciences) utilizing 10µl of RNA
template and forward and reverse primers designed specifically
for the LCMV glycoprotein (GP). Real-time quantitative PCR
of LCMV viral cDNA was performed using LCMV GP primers
and Sybr Green Master Mix (Fermentas and analyzed using
StepOne Plus Real Time PCR system. Resulting CT-values were
used measured against a standard curve generated from the
LCMV-Arm53b plasmid (gift of Addgene plasmid #15796)
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FIGURE 1 | METH levels in plasma during chronic exposure and
LCMV infection. (A) Experimental scheme of METH administration and
LCMV infection. (B) ELISA was performed to measure steady-state METH
levels after the different time-points indicated. Results are expressed as Mean
± SE of at least 5 measurements from each group at each time-point. METH
vs. LCMV-METH **p < 0.01 at day 3. (C) Measurement of body weight after
METH treatment in LCMV infected mice. Body weights of mice before and
after METH administration and infection were measured and expressed as
grams (Mean ± SE of at least 10 mice per group). Body weights significantly
decreased with METH at very early infection **p < 0.01 and ***p < 0.001.
of known copy numbers to calculate average log viral copy
numbers/mL of plasma (Pal et al., 2014). Samples and standards
were performed in triplicate with five animals per experimental
condition.
Flow Cytometry
Splenocytes extracted from LCMV infected mice were subjected
to FACS analysis on a FACS Canto II (BD Biosciences). The
lymphocyte population was gated based on forward and side
scatter. T lymphocyte population was gated using CD3 and
further divided as CD4+ and CD8+ subsets. After washing,
splenocytes were resuspended in R10 media containing LCMV
Peptide 69 (Proimmune, epitope of GP1, 1µg/ml) and Brefeldin
A (Ebioscience, 1µl/ml). After incubation for 5–6 h at 37◦C,
cells were centrifuged, washed and then stained with PE labeled
Pro5 R©MHC class I Pentamer (Proimmune, 10µl/test) specific to
allele H-2Db and other fluorescence conjugated antibodies to cell
surface markers and intracellular cytokines for flow cytometric
analysis. The following antibodies were used for staining: CD3
APC-Cy7, CD4 AmCyan, CD8 Pacific Blue, LCMV Pentamer
PE, CD279 (PD1) PECy7, CD25 PerCpCy5.5, CD69 APC, CD27
PeCy7, CXCR3 PerCpCy5.5, and EGFR FITC (antibodies were
from eBiosciences, San Diego, and BD Biosciences, CA, USA).
Stained cells were then acquired on a FACS Canto II (BD
Biosciences) using FACSDiva software (BD Biosciences, V 6.1.3).
Cells were gated using isotype control as negatives (Figure S1
in Supplementary Material). A representative plot for the gating
strategy for CD3+, CD4+, and CD8+ is shown in Figure 3A. At
least 10,000 lymphocyte events were recorded. Recorded data was
plotted and further analyzed using FlowJo software (TreeStar V
9.4). Values from FlowJo were transferred into GraphPad Prism
(v. 4.0, GraphPad Software) for statistical analysis.
Serum Cytokine Analysis
Mouse blood was collected from submandibular vein at different
time points and serum was separated. Multiplex mouse cytokine
analysis was performed using Meso-scale Discovery R© (MSD)
multi-array system as per manufacturer’s protocol. Briefly 25µl
of serum was applied into MSD ELISA, and cytokine levels
were estimated using provided standards and calculated by MSD
reader software (Meso Scale Discoveries, Rockville, MD, USA).
Statistical Analysis
Data were analyzed using Prism software (GraphPad, San Diego,
CA). One sample t-test, two-tailed Student’s t-test or One-Way
ANOVA, as appropriate, was used as statistical test for different
sets of experiments, and considered significant values at p < 0.05
(marked in the figures as ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001).
Results
METH Levels in Plasma during Chronic Exposure
and LCMV Infection
We analyzed METH levels in the plasma at different time points
after LCMV infection, to determine if levels of METH were
affected during viral infection. In our model, chronic exposure of
10mg per day METH was well-tolerated up to 56 days (data not
shown). Steady-state plasma METH levels were analyzed up to
28 days (Figure 1B). Plasma METH levels was analyzed 2 h after
METH injection at each time-point and the levels were steadily
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at about 2000 pg/µl and sustained for up to 28 days. Several
studies have reported the levels of METH in plasma and other
organs in human, murine and rodent species (Riviére et al., 2000;
Volkow et al., 2010; Loftis et al., 2011) after various routes of
injection. Our analysis via s.c. route also show that steady-state
METH levels in circulation is close to what has been reported
in these studies between 1000 and 2000 pg/µl after about 2 h of
METH administration (Riviére et al., 2000). Interestingly, plasma
METH levels were significantly lower in the LCMV infected mice
at day 3 as compared to METH alone but quickly normalized
and remained unaltered between the two groups up to 28 days
of analysis (in pg/µl, METH—2053 ± 68.0 vs. METH-LCMV—
1470 ± 113) (Figure 1B). METH is mainly metabolized in the
liver and the LCMV virus (clone 13) also has been shown to
infiltrate the liver by the first week of infection (Beura et al., 2015).
One plausible speculation could be that high viremia during
early stage of infection might have an effect on the metabolism
of METH in the liver and release in circulation. In addition,
hepatic and renal clearance also contribute to the elimination of
METH. Quantitative excretion profile of METH and its levels in
organs could help further address the differences. While the body
weights were lower in the initial two weeks of LCMV infection
in the METH treated group (LCMV—17.4 ± 0.4 g vs. LCMV-
METH—16.0± 0.3 g), for the rest of the time up to 8 weeks there
was no difference in the body weights between the METH treated
LCMV infected mice and LCMV alone (Figure 1C).
METH Treatment does not Alter Plasma or Organ
Viral Load in Chronic Persistent LCMV Infection
We analyzed the LCMV viral load in circulation (plasma—
Figure 2A) and also in the organs (spleen and lungs—
Figures 2B,C, respectively) by quantitative PCR after chronic
METH exposure. There was a small but significant increase
in the viral load in the plasma at day 3 in METH group
than without (LCMV—6.4 ± 0.2 vs. LCMV-METH—7.0 ±
0.2 average log copy numbers/ml; n = 24 in each group;
p < 0.05), that quickly normalized as the infection proceeded
(Figure 2) suggesting METH affects viral infection at very early
stages of viral replication. Our observation is in concordance
with Bourne’s group (Valencia et al., 2012) that showed similar
increase in Herpes simplex virus upon METH treatment by day
three post-infection, in a mouse model. Plasma, spleen, and lungs
showed similar viral titer by day 14. However, the viral loads with
or without METH at any later time points, either in plasma or in
the organs were not different (Figure 2) indicating that chronic
exposure did not affect the viral replication throughout the time
of the study. Similar observations have been made in the herpes
simplex virus model that is studied in the presence of METH
as well (Valencia et al., 2012). Viral load peaked at day 14 and
decreased steeply between day 28 and 56 in plasma, spleen and
lungs, in both the infected mice with or without METH. This
observation is similar to the trend in chronic infection observed
in other studies (Matloubian et al., 1994). In mice, LCMV viral
replication in most tissues is controlled by 3 months post-
infection, but the virus persists in some tissues for life (Ahmed
and Oldstone, 1988; Wherry et al., 2003; Kao et al., 2011).
METH Treatment Significantly Increases Total
CD3+ but Slightly Alters Percentages of CD4+
and CD8+ T cell Subsets in Spleen at Early
Stages of Chronic LCMV Infection
METH administration affects a vast repertoire of immune
cells including natural killer cells, dendritic cells, monocytes,
macrophages, and granulocytes (Harms et al., 2012). T cells play
a critical role in orchestrating immune responses and METH has
been shown to adversely impact T cell responses, especially in
HIV infection (In et al., 2005; Martinez et al., 2009). Chronic
LCMV infection in mice causes huge alterations in the T cell
immune subsets in the spleen (Khanolkar et al., 2002). To study
if chronic METH exposure altered these changes in the CD4+
and CD8+ T cell compartments, we analyzed changes in total
CD4+ and CD8+T cells as well as antigen specific CD8+ subsets
FIGURE 2 | METH treatment does not alter plasma or organ viral
load in chronic LCMV infection. LCMV viral load in plasma (A), spleen
(B), and lungs (C) was measured by RT-PCR. Real-time quantitative PCR
of LCMV viral cDNA was performed using LCMV GP primers and Sybr
Green Master Mix. A standard curve was generated from the
LCMV-Arm53b plasmid to calculate the copy numbers. Samples and
standards were performed in triplicate with five animals per experimental
condition.
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FIGURE 3 | METH treatment alters percentages of CD3+ but not CD4+
and CD8+ T cells in spleen at early stages of chronic LCMV infection.
Splenocytes extracted from LCMV infected mice with or without METH
exposure, were surface stained with CD3, CD4, CD8, and Pentamer specific
CD8+, markers after antigen specific stimulation against Peptide 69. (A)
Gating strategy for flow cytometric analysis. (B) Percentages of CD3+, CD4+,
CD8+, and Pentamer specific T cell populations are shown as Mean ± SE of
at least 8 mice per group. CD3 surface marker was significantly increased in
the METH treated LCMV infected group than LCMV alone; ***p < 0.001.
using Pentamer staining. A representative plot for the gating
strategy for CD3+, CD4+, and CD8+ is shown in Figure 3A.
To our surprise, we did not see any marked differences in the
CD4 and CD8 T cell populations or the percentage of antigen
specific CD8+ T cells, between METH treated infected mice and
infected alone (Figure 3B). It has to be noted that the total CD4+
cells did not change much during the course of infection while
CD8+ T cells increased significantly by day 56 (Mean percent ±
SE–CD4+ LCMV–day 14–32.7±2.4; day 28–44.0±3.1; day 56–
41.7± 2.7; CD8+ LCMV–day 14–17.2± 1.6; day 28–22.2± 4.8,
day 56–28.9 ± 3.9, day 14 vs. day 56 ∗p < 0.01), and METH did
not modulate the CD4+ or CD8+ expression at later time points
as well (data not shown). We did see an increased percentage of
CD8+ T cells upon METH treatment as compared to no METH
controls in uninfected mice (data not shown) at day 14. We also
saw a significant increase in the total CD3+ T cells at day 14
upon METH treatment in infected mice (LCMV—39.3 ± 2.0 %
vs. LCMV-METH—61.9±4.3%; ∗∗∗p < 0.001—Figure 3B). The
increase in CD3+ cells upon METH in the infected group may
suggest that these cells may be activated. Peerzada et al. have
shown a strong decrease in the splenic CD3+ cells upon METH
treatment (Peerzada et al., 2013) that we did not observe in our
uninfected METH /no METH study groups (data not shown).
METH Induces Significant Increase in PD-1 in the
Splenic CD4+ and CD8+ T cells at Early Stages
of Chronic LCMV Infection
CD8 T cells undergo depletion or functional inactivation also
known as exhaustion in chronic viral infection. The functional
exhaustion of CD8 T cells has been shown to correlate with
PD-1 expression (Blattman et al., 2009; Kao et al., 2011;
Penaloza-MacMaster et al., 2014) and the first studies to
demonstrate this comes from LCMV chronic mouse model
(Barber et al., 2006). Therefore we analyzed the expression of this
important inhibitory marker in a chronic METH environment.
We hypothesized that chronic METH exposure augments the
expression of the inhibitory receptor PD-1 in the LCMV chronic
infection model and indeed we saw a significantly increased PD-
1 expression in the METH treated infected group at day 14 both
in the CD4+ and CD8+ T cells than the non-METH infected
mice (Figure 4). However, the effect with METH treatment was
seen only at day 14 and normalized as the infection progressed
(Figure 4). There was a significant decrease in the CD4+ and
CD8+ cells expressing PD-1 by day 28 after which the expression
plateaued up to day 56 (LCMV—CD4+PD-1+—day 14 vs. 28—
∗p < 0.05; CD8+PD-1+—day 14 vs. day 28—∗∗∗p < 0.002—
Figure 4). Presence of METH did not change the expression
of PD-1 at these time-points probably because the cells were
already functionally exhausted. PD-1 increase byMETH suggests
that chronic METH exposure might augment CD8+ T cells
exhaustion thus making them functionally inactive to evoke any
anti-viral immunity. CD4+ T cell help is essential to raise and
maintain an efficient CD8 response (Matloubian et al., 1994).
Increase in PD-1 in the CD4+ T cells therefore suggests that the
CD4+ T cells also undergo exhaustion in the presence of METH
and the required CD4+ T cell help to evoke CD8+ responses is
diminished as well (Matloubian et al., 1994; Han et al., 2010).
METH Modulates CD69, CD25, and CD27
Activation Markers in the Splenic T cell Subsets
in Chronic LCMV Infection
One of the earliest cell surface antigens expressed by T cells
following activation is CD69, a member of the C-type lectin
superfamily (Marzio et al., 1999). Once expressed, CD69 acts as
a costimulatory molecule for T cell activation and proliferation.
We analyzed the expression of CD69 in the context of LCMV in
a METH environment. There was a significant increase in CD69
marker on CD8 T cells at day 14 (p < 0.05) (Table 1) while
METH did not induce differential expression of this marker at
other time points. Although not statistically significant a similar
trend of increased CD69 expression was noted on CD4+ T cells
at day 14 and day 28 post-infection (Table 1). The expression
of CD69 significantly decreased during the course of infection
(CD4–LCMV—day 14 vs. day 56—∗∗p < 0.01; CD8-LCMV—
day 14 vs. day 56—∗p < 0.05). The induction of CD69 by METH
at early time-point during viral infectionmight play an important
role in regulation of the subsequent immune responses.
CD25 is the alpha chain of the IL-2 receptor. The
CD4+CD25+ subset alone or along with the expression of FoxP3
is often referred to as T suppressor/T regulatory subset (Hori
et al., 2003). We analyzed the modulation of CD25 in both CD4
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FIGURE 4 | METH induces significant increase in PD-1 in the
splenic CD4+ and CD8+ T cells at early stages of chronic
LCMV infection. Splenocytes extracted from LCMV infected mice with
or without METH treatment, were surface stained after antigen specific
stimulation, with CD3, CD8, CD4 and PD-1(CD279) markers to analyze
the classic activation with LCMV infection. FACS analysis was
performed and analyzed as described in Methods section. METH
significantly increased PD-1 expression by day 14 of infection both in
CD8 (*p < 0.05) (B) and very significantly in the CD4 (***p < 0.001) (A)
T cells.
TABLE 1 | Modulation of activation markers on CD4+ and CD8+ T cells induced upon LCMV infection by chronic METH exposure.
Activation marker T cell subset Treatment Days post infection
14 28 56
CD69 CD4 LCMV 36.8± 3.1 23.1±2.8 17.1± 3.6**
LCMV-METH 46.9± 8.1 26.7±3.7 17.2± 1.8**
CD8 LCMV 19.5± 2.2 21.2±4.0 11.5± 2.7**
LCMV-METH 33.1± 8.5* 23.7±4.4 9.1± 2.1*
CD25 CD4 LCMV 35.5± 7.2 24.4±9.4 18.5± 4.0
LCMV-METH 29.6± 3.1 22.3±5.4 29.6± 7.2
CD8 LCMV 5.8± 1.1 5.1±2.8 6.5± 1.9
LCMV-METH 6.8± 0.9 4.4±0.9 4.7± 1.0
CD27 CD4 LCMV 8.4± 2.0 5.6±1.7 3.7± 0.6
LCMV-METH 5.9± 1.3 4.8±1.0 4.7± 1.0
CD8 LCMV 8.2± 1.8 6.2±1.7 5.5± 1.4
LCMV-METH 7.8± 1.5 5.8±1.0 5.0± 1.3
Splenocytes extracted from LCMV infected mice, with or without METH treatment, were surface stained after antigen specific stimulation for (1) T cell markers: CD3, CD8, and CD4
and (2) activation markers: CD69, CD25, and CD27. FACS analysis was performed and analyzed as described in Materials and Methods Section. Numbers are percent positive cells
for the respective marker. METH significantly increased the CD69 marker on CD8 T cells of the LCMV-METH group vs. LCMV on day 14 (*p < 0.05). CD69 was significantly decreased
over the course of infection; d14 vs. d56–**p < 0.01 for CD4 and *p < 0.05 for CD8 subsets. METH did not significantly alter the expression of either CD25 or CD27 at any time point
analyzed.
and CD8 T cell compartments. The percentages of CD4+CD25+
were only slightly altered by METH and did not change much in
the CD8 compartment as well as in the infected groups (Table 1).
METH did not alter the expression of CD25 in CD4+ or CD8+
cells without infection as well (data not shown).
CD27 is a member of Tumor necrosis factor receptor (TNFR)
family members that play key roles in control of both acute
and persistent or latent infections (Welten et al., 2013). CD27
is constitutively expressed on naive T cells. Analysis of this
marker in the LCMV infected group with or without METH
showed slight decrease in the CD27 expression at day 14 in
the METH than the no METH CD4+ subset (Table 1), but no
significant alterations in the percentages of this marker on CD4+
or CD8+ cells at any other later time points analyzed. It has been
shown that during acute (Armstrong) or chronic LCMV (clone
13) infection, CD27 initially increases and then returns to the
baseline levels with T cells remaining CD27-positive throughout
the infection (Welten et al., 2013; Mbanwi and Watts, 2014).
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Our observation in the LCMV infected group is similar to these
reports. However, our results suggest that METH may not affect
expression of this marker on splenic T cells.
Overall, none of the markers of classic T cell activation was
greatly modulated by METH during LCMV infection, suggesting
that METH did not directly affect T cell activation via the
expression of these markers but may alter T cell function via
cytokine production that may be mediated by other pathways.
CXCR3 Expression on Splenic T cell Subsets is
Exacerbated in METH Administered LCMV Mice
CD8 T cells alter their expression of chemokine receptors upon
activation by both antigen and innate stimuli (Christensen et al.,
2006; Kroll et al., 2014; Torraca et al., 2015). It has been shown
that inflammatory chemokine receptors, such as CXCR3, CXCR6,
and CCR5, are upregulated during infection. We analyzed in
our model if METH altered CXCR3 expression and found that
CXCR3 expression on both CD4+ and CD8+ T cells was very
significantly upregulated in the METH treated infected group
than LCMV alone by day 14, and this increase although not
significant was persistent up to 56 days in CD4+ (Figure 5A) but
not CD8+ T cells (Figure 5B). Alteration in CXCR3 expression
has been shown to affect induction of central and effector
memory T cell responses (Hu et al., 2011). Our current findings of
increased CXCR3 suggest an important role of METH in altering
the recruitment of T cells and probably generation of memory
response.
Chronic METH Treatment Increases EGFR
Expression on Splenic T cells Subsets in LCMV
Infection
In recent years, increasing evidence has shown that viruses can
interact with and modulate epidermal growth factor receptor
(EGFR) activity to facilitate viral entry, replication or the evasion
of host immune surveillance (Zheng et al., 2014). Furthermore,
EGFR is a receptor tyrosine kinase that regulates cellular
homeostatic processes (Mendelsohn and Baselga, 2006). The
responses that are induced by ligand binding to EGFR, including
cell signaling activation, protein kinase phosphorylation, and
cytoskeletal network rearrangement, resemble those induced by
virus infection (Diehl and Schaal, 2013). Intriguingly CD4+
(Figure 6A) and CD8+ (Figure 6B) T cells showed a significant
increase of EGFR expression in the METH exposed LCMV
infected group than LCMV alone by 56 days post infection,
while a trend of increased expression in the METH treated group
was observed at all time-points analyzed (Figure 6). In LCMV
infected mice alone, EGFR expression in both CD4+ and CD8+
T cells decreased in a time dependent manner. The difference
in the expression reached significance only at day 56 because
the viral infection per se steeply decreased EGFR expression. As
EGFR has been shown to facilitate viral entry, this decrease in
expression could be a way the host immune system is responding
to evade further infection. This data is very interesting and
clearly indicates that chronic METH exposure increases EGFR
that probably increases permissiveness of viruses and be in favor
of establishing infection. We are interested to pursue further the
molecular aspects of this observation.
LCMV Induced Cytokine Profile is Altered in the
Presence of METH
Experimental data from numerous systems demonstrate that
CD8 and CD4 T cell responses co-operate to control viral
infections by production of cytokines as well as inducing
target cell lysis. We analyzed the production of the signature
proinflammatory (Figure 7A) and Th2 cytokine profile
(Figure 7B) in the serum. LCMV infection induced a very good
titer of all the major proinflammatory cytokines (TNF, IL12p70,
IL1β, IL-6) by day 7 that gradually decreased as infection
proceeded. METH significantly decreased the production of both
the major proinflammatory cytokines, TNF, and IL-12 in serum
FIGURE 5 | CXCR3 expression on splenic T cell subsets is
exacerbated in METH administered LCMV mice. Splenocytes extracted
from LCMV infected mice with or without METH treatment, were surface
stained after antigen specific stimulation with CD3, CD8, CD4 and CXCR3
markers. FACS analysis was performed and analyzed as described in
Methods section. METH significantly increased CXCR3 expression by day 14
of infection both in CD4 (**p < 0.01) (A) and CD8 (***p < 0.001) (B) T cells
and persistent increase was seen in CD4 T cells at later time-points as well
when compared to no METH LCMV infected group. However, the expression
levels induced by METH significantly dropped from day 14 during the course
of infecion (**p < 0.01), while infection per se without METH did not alter
CXCR3 expression levels.
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FIGURE 6 | Chronic METH treatment increases EGFR expression
on splenic T cell subsets in LCMV infection. Splenocytes
extracted from LCMV infected mice with or without METH treatment,
were surface stained after antigen specific stimulation with CD3,
CD8, CD4 and EGFR markers. FACS analysis was performed and
analyzed as described in Methods section. METH significantly
increased EGFR expression at later stages of infection both in CD4
(A) and CD8 (B) T cells. EGFR expression was significantly
decreased during the course of infection both in CD4 and CD8 T
cells; (*p < 0.05; **p < 0.01).
by day 14 (Figure 7A). AlthoughMETH exposed LCMV infected
mice showed decreased titers of the cytokines than LCMV alone,
the differences did not reach significance as infection proceeded.
IFNγ levels, however was very high at day 7 that drastically
dropped to baseline by day 14 and not seen in circulation
anymore until the end of the study. METH did not alter IFNγ
levels at day 7 or any other time point. TNF is a very important
proinflammatory cytokine and IL12 is an important cytokine that
determines the Th1 fate. The other cytokines that we analyzed
as part of the proinflammatory profile (IL1β, and KC/GRO)
showed a decreased production in the METH treated group than
without, although the values did not reach significance. KC/GRO
is a CXC related protein that is mainly secreted by macrophages
and is a chemoattractant for neutrophils (Shiratori et al., 1994).
It is part of the proinflammatory profile that is altered in chronic
viral infections.
We found that IL-2 levels in the serum was decreased at
all time-points in the LCMV-METH group than LCMV alone
(Figure 7B), in concordance with what we reported in human
PBMCs (Potula et al., 2010). The regulatory cytokine IL-10 was
also decreased upon METH exposure at early time-points, while
levels of the Th2 cytokines, IL-4 and IL-5 remained unaltered. In
all, the cytokine data indicate that METH profoundly affected the
Th1/proinflammatory responses.
Discussion
It is now well-established that METH abusers, as other
drugs of abuse, are at increased risk of various infectious
diseases. METH is typically administered nasally, intravenously
or orally, and METH users experience feelings of euphoria,
hyperactivity, reduced appetite, sleeplessness, and arousal after
administration (Cruickshank and Dyer, 2009). Effects of METH
on systemic immune responses have been typically studied using
intraperitoneal or intravenous administration (Harms et al.,
2012). In this report, we have analyzed the effects of METH
upon subcutaneous (s.c.) administration, and show that METH
profoundly affected the immune response in the chronic LCMV
infection model.
Irrespective of the route of administration, METH is
metabolized largely in the liver. Unfortunately we could not
assess the levels of METH in the liver due to technical
issues. Studies indicate that metabolism does not appear to
be altered by chronic exposure (Volkow et al., 2010). The
terminal plasma half-life of METH of approximately 10 h is
similar across administration routes, but with substantial inter-
individual variability. Our results show approximately 1000–2000
pg/µl of METH after 2 h of s.c. injections that is consistent
with other studies with any other route of injection (Riviére
et al., 2000). Also in our study, METH effects on body weight
of the infected animals were mostly impacted during the
early weeks, as the viral replication was also higher at this
time. METH injection has been shown to cause approximately
2 g-weight loss in mice in a chronic administration study
(Martinez et al., 2009). In another study, oral administration of
amphetamines in mice revealed no difference in body weights
between treatment and control groups (Kwack et al., 2014),
indicating that METH effects on growth may depend on route of
administration.
LCMV has proven to be a great model to study chronic
infections in mice as they induce a robust T cell response. Our
finding of a significant increase in LCMV viral loads at day 3 in
theMETH treated group is consistent with other reports showing
that METH increases viral replication and so the increased viral
load seen in circulation. Intriguingly the levels normalize as the
infection proceeds, and with or withoutMETH show similar viral
loads even up to the end of the study (56 days) (Figure 2). METH
effects did not impact viral loads in tissues in our model while in
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FIGURE 7 | LCMV induced cytokine profile is altered in the
presence of METH. Mouse cytokines in serum were measured using a
Meso Scale Discovery (MSD) multiplex 7-spot electrochemiluminescence
(ECL) assay and outputs measured by an ultra low noise charge-coupled
device (CCD) Imager 2400 (Meso Scale Discovery, Gaithersburg, MD,
USA). Sera was collected from the LCMV infected mice with or without
METH exposure at days 7, 14, 28, 42, and 56 post-infection. (A) The
proinflammatory cytokines measured included TNF, IFNγ, IL12p70, IL-1β,
IL-6 and KC/GRO. (B) The cytokines measured to analyze the Th2 profile
included IL-2, IL-10, IL-4 and IL-5 (*p < 0.05; ***p < 0.001). METH
decreased IL-2 levels in the serum at all time-points analyzed; however
the statistics did not reach significance.
a HSVmodel a modest increase is shown in tissue in the presence
of METH (Valencia et al., 2012).
Antigen specific CD8 T cells undergo rapid clonal expansion
in response to infection with intracellular pathogens and
differentiate into cytotoxic effector T cells that control the
infection through lysis of the infected cells and production of
cytokines (Williams and Bevan, 2007). CD4 Th cells are pivotal
and orchestrate the immune response and differentially activate
diverse branches of innate and adaptive immunity to direct
the appropriate response to an invading pathogen. CD4 Th1
immunity is critical to sustain residual CD8 T-cell activity to
control infection during persistent infection and is characterized
in CD4 T cells by the secretion of IFN-γ, TNF-α, and IL-2 (Szabo
et al., 2003; Ng et al., 2013). We did not find any dramatic
alterations in the percentages of either total CD4+ or CD8+ T
cells in the spleen upon chronic METH exposure in the spleen,
suggesting that METH may not alter the total percentages of the
cells but probably their functional capability. Alterations in the
CD4+ and CD8+ T cells upon METH administration have been
shown to be very variable upon different routes of administration.
While the CD4+ T cells have been shown to be decreased and
CD8+ to be increased in a rat self-administration model of
METH (Mata et al., 2015), another study using oral route showed
the opposite (In et al., 2005) and one that used intra peritoneal
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route showed decreased percentage of both CD4+ and CD8+ T
cells (Harms et al., 2012). Nonetheless, we did see a significant
increase in the total CD3+ T cells that probably indicates overall
activation.
Exhaustion of CD8+ T cells, defined as the progressive loss
of functions caused by ongoing antigen exposure and is a major
factor leading to defective pathogen clearance in chronic viral
infections. Studies in the murine LCMV model have identified
PD-1 as a critical mediator of this immune impairment. Blockade
of the PD-1 pathway is considered a promising approach in both
infectious diseases and cancer (Porichis et al., 2011). Porichis
et al. (2011) have demonstrated in HIV infected patients, that
PD-1 impairs HIV-specific T helper responses both by limiting
expansion of these cells and by inhibiting effector functions
of multiple differentiated CD4 T-cell subsets and that blocking
these responses can overcome these effects. We found METH
significantly upregulated PD-1 on both CD4+ and CD8+ T
cells in our chronic LCMVmodel, suggesting METH profoundly
affected both CD4+ and CD8+ T cells to go into exhaustion.
The expression of PD-1 at later stages of infection for both
CD4+ and CD8+ T cells was similar between the METH
treated or untreated infected mice. This may be because, as the
infection progressed METH no longer influenced the already
exhausted cells and therefore we did not see much variation in
the percentages of cells expressing thesemarkers, correlating with
the trend of chronic infection (Petrovas et al., 2013).
One of the earliest classic cell surface antigens expressed by T
cells following activation is CD69. The function of CD69 on T
lymphocytes acting as a costimulatory molecule in proliferation
and lymphokine secretion is well-established (Borrego et al.,
1999). The kinetics of CD69 expression in both subsets of T
cells decreased during the course of infection. The reasons for
this dynamic regulation of CD69 are not clear but it is probable
that there might be a period of time later during infection
when T cells are refractory to further upregulation of CD69. By
contrast, METH increased CD69 expression of CD8+ T cells at
early infection indicating increased activation. It has also been
shown that upregulation of CD69 expression inhibits lymphocyte
migration and T cells remain at the site of infection (Feng
et al., 2002; Shiow et al., 2006). METH may have an important
impact on T cell migration and may alter further consequences
in the immune response, including generation of T cell memory.
However, expression of both CD25 and CD27 markers were not
much affected by METH at any time point analyzed either on
the CD8+ or CD4+ T cells. The expression of CD69 and CD25
has been found to be dissociated in various situations as for
example in normal pregnancies where CD25 is actually decreased
and CD69 is increased (Chao et al., 2002). We observed that
CD25, the high affinity IL-2 receptor that is shown to be induced
upon this cytokine (Raué et al., 2013), did not alter much in the
splenic T cell populations, probably correlating with the decrease
in IL-2 uponMETH treatment and non-activation of this marker.
CD27 belongs to the tumor necrosis factor receptor (TNFR)
family and has also been used as a marker to identify memory
precursor CD8+ T cells (Prasad et al., 1997; Joshi and Kaech,
2008). During acute (Armstrong) or chronic LCMV (clone
13) infection, CD27 initially increases and then returns to the
baseline levels with T cells remaining CD27-positive throughout
the infection (Welten et al., 2013; Mbanwi and Watts, 2014).
Our observation in the LCMV infected group is similar to these
reports.
A major impact of METH in our study, besides PD-1
upregulation, was the strong increase in themigratory chemokine
marker CXCR3. Activated Th1 CD4 T cells and effector CD8
T cells (Moser and Loetscher, 2001; Hu et al., 2011) express
this receptor, and promote migration of activated CD8 T cells
into non-lymphoid tissue infection sites under the influence
of the chemokine ligands CXCL9 and CXCL10 (Weng et al.,
1998; Christensen et al., 2006). Proteomic analysis of immature
dendritic cells revealed a very strong increase of CXCR3 in
METH treated cells than controls, implicating the role of METH
in regulating migration (Reynolds et al., 2007). In this study
we did not see any huge differences in the CXCR3 expression
on CD4 or CD8 T cells between control and METH in the
uninfected group (data not shown). The upregulation of CXCR3
upon infection in a METH environment has a strong implication
that METH can affect CD8 T cell responses as well as generation
of memory response. Matloubian’s group have demonstrated in
a chronic LCMV infection model that absence of CXCR3 leads
to generation of more long-lived memory CD8 T cells with a
qualitatively better recall response(Hu et al., 2011), tying with
our findings to suggest that increase in CXCR3 upon METH
treatment may evoke a poor memory response.
EGFR has also been confirmed as a co-receptor for the
entry of viruses such as human cytomegalovirus (HCMV) and
adeno-associated virus serotype 6 (AAV6) (Weller et al., 2010;
Diehl and Schaal, 2013; Zheng et al., 2014). In addition, EGFR-
mediated different signaling cascades have also been implicated
to facilitate viral replication or viral pathogenesis, such as EBV
(Kung et al., 2011) and Pichindé virus (Bowick et al., 2007). With
this background we aimed to test if METH modulated EGFR
expression on LCMV infected T cells. The increased expression
of EGFR in the METH treated infected animals at all time-points
probably suggests thatMETHmight help promote viral entry and
we speculate that upon EGFR signaling may also impact viral
pathogenesis. In this study, the persistent elevated expression
of EGFR observed in chronically infected mice exposed to
METH compared to infection alone is worth noting. As more
evidence are accumulating (Weller et al., 2010; Kung et al.,
2011; Zheng et al., 2014) showing the importance of EGFR on
viral entry andmaybe pathogenesis, this interesting phenomenon
certainly warrants further investigation at the molecular level. It
will be interesting to determine the relationship between EGFR
expression and PD-L1/PD-1 axis (Chen et al., 2015) in T cells
in a chronic infection setting under the influence of stimulant-
induced microenvironment.
While we saw interesting alterations caused by METH
exposure in many of the important markers induced during
chronic LCMV infection in the spleen, due to technical problems,
we could not assess the impact on immune cells in the blood,
which probably could have explained if this pattern is specific
to secondary lymphoid organs as spleen. Nonetheless, changes in
the cytokine profile in serum are representative of some of the
effects of METH during the entire course of infection.
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Chronic METH exposure via s.c. route majorly resulted in a
dampened proinflammatory cytokine profile upon infection. We
did find suppressed IL-2 levels throughout the study consistent
with our earlier report on decreased IL-2 levels in T cells upon
METH treatment (Potula et al., 2010). Brooks et al. have shown
that persistent viral infection in mice results in a significant
upregulation of interleukin IL-10 by antigen-presenting cells,
leading to impaired T-cell responses (Brooks et al., 2006;
Wilson and Brooks, 2011). Intriguingly, METH at early time
points decreased IL-10 in circulation with infection than METH
untreated infected mice, but quickly normalized as infection
progressed. The role of IL-10 as a regulatory cytokine is still
complex (Wilson and Brooks, 2011). Analysis of METH effects
on plasma cytokines after s.c. administration, in mice and of
METH dependent human subjects, revealed a lot of variation in
the expression of IL-2 and IL-10 in both human and mice (Loftis
et al., 2011). Alterations in the cytokine profile by METH may
also be tissue specific as indicated by a significant upregulation of
cytokines in the hippocampal tissue in mice (Loftis et al., 2011).
Our study indicates that chronic METH exposure via
s.c. route alters systemic and peripheral immune responses.
METH modulates key markers on T cells involved in LCMV
pathogenesis. These findings of increase in inhibitory phenotype,
PD-1, indicates that METH enhances T cell exhaustion. The
significant increase of CXCR3 upon chronic METH exposure
suggests that METH may not only play an important role in
recruitment of CD8 T cells to elicit immune response but also
a key player in modulating the generation of memory response.
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Figure S1 | Splenocytes extracted from LCMV infected mice with or
without METH treatment, were surface stained after antigen specific
stimulation with CD3, CD8, CD4 along with activation markers. FACS
analysis was performed and analyzed as described in Materials and Methods
Section. (A) Representative histograms of CD3, CD4, and CD8 expression are
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already gated on CD3 and analyzed in CD4 or CD8 subset. Isotypes for the
respective antibodies are plotted in shaded gray for all activation markers.
References
Ahmed, R., and Oldstone, M. B. (1988). Organ-specific selection of viral
variants during chronic infection. J. Exp. Med. 167, 1719–1724. doi:
10.1084/jem.167.5.1719
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H.,
et al. (2006). Restoring function in exhausted CD8 T cells during chronic viral
infection. Nature 439, 682–687. doi: 10.1038/nature04444
Beura, L. K., Anderson, K. G., Schenkel, J. M., Locquiao, J. J., Fraser, K. A., Vezys,
V., et al. (2015). Lymphocytic choriomeningitis virus persistence promotes
effector-like memory differentiation and enhances mucosal T cell distribution.
J. Leukoc. Biol. 97, 217–225. doi: 10.1189/jlb.1HI0314-154R
Blattman, J. N., Wherry, E. J., Ha, S. J., van der Most, R. G., and Ahmed, R. (2009).
Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during
chronic infection. J. Virol. 83, 4386–4394. doi: 10.1128/JVI.02524-08
Borrego, F., Robertson, M. J., Ritz, J., Peña, J., and Solana, R. (1999). CD69 is a
stimulatory receptor for natural killer cell and its cytotoxic effect is blocked
by CD94 inhibitory receptor. Immunology 97, 159–165. doi: 10.1046/j.1365-
2567.1999.00738.x
Bowick, G. C., Fennewald, S. M., Scott, E. P., Zhang, L., Elsom, B. L., Aronson, J.
F., et al. (2007). Identification of differentially activated cell-signaling networks
associated with pichinde virus pathogenesis by using systems kinomics. J. Virol.
81, 1923–1933. doi: 10.1128/JVI.02199-06
Brooks, D. G., Trifilo, M. J., Edelmann, K. H., Teyton, L., McGavern, D. B., and
Oldstone, M. B. (2006). Interleukin-10 determines viral clearance or persistence
in vivo. Nat. Med. 12, 1301–1309. doi: 10.1038/nm1492
Chao, K. H., Wu, M. Y., Yang, J. H., Chen, S. U., Yang, Y. S., and Ho, H. N. (2002).
Expression of the interleukin-2 receptor alpha (CD25) is selectively decreased
on decidual CD4+ and CD8+ T lymphocytes in normal pregnancies. Mol.
Hum. Reprod. 8, 667–673. doi: 10.1093/molehr/8.7.667
Chen, N., Fang, W., Zhan, J., Hong, S., Tang, Y., Kang, S., et al. (2015).
Upregulation of PD-L1 by EGFR activation mediates the immune escape in
EGFR-Driven NSCLC: implication for optional immune targeted therapy for
NSCLC patients with EGFR mutation. J. Thorac. Oncol. 10, 910–923. doi:
10.1097/JTO.0000000000000500
Christensen, J. E., de Lemos, C., Moos, T., Christensen, J. P., and Thomsen,
A. R. (2006). CXCL10 is the key ligand for CXCR3 on CD8+ effector T
cells involved in immune surveillance of the lymphocytic choriomeningitis
virus-infected central nervous system. J. Immunol. 176, 4235–4243. doi:
10.4049/jimmunol.176.7.4235
Cruickshank, C. C., and Dyer, K. R. (2009). A review of the clinical
pharmacology of methamphetamine. Addiction 104, 1085–1099. doi:
10.1111/j.1360-0443.2009.02564.x
Diehl, N., and Schaal, H. (2013). Make yourself at home: viral hijacking of the
PI3K/Akt signaling pathway. Viruses 5, 3192–3212. doi: 10.3390/v5123192
Ellis, R. J., Childers, M. E., Cherner, M., Lazzaretto, D., Letendre, S.,
and Grant, I. (2003). Increased human immunodeficiency virus loads in
active methamphetamine users are explained by reduced effectiveness of
antiretroviral therapy. J. Infect. Dis. 188, 1820–1826. doi: 10.1086/379894
Feng, C., Woodside, K. J., Vance, B. A., El-Khoury, D., Canelles, M., Lee, J., et al.
(2002). A potential role for CD69 in thymocyte emigration. Int. Immunol. 14,
535–544. doi: 10.1093/intimm/dxf020
Han, S., Asoyan, A., Rabenstein, H., Nakano, N., and Obst, R. (2010). Role
of antigen persistence and dose for CD4+ T-cell exhaustion and recovery.
Proc. Natl. Acad. Sci. U.S.A. 107, 20453–20458. doi: 10.1073/pnas.10084
37107
Harms, R., Morsey, B., Boyer, C. W., Fox, H. S., and Sarvetnick, N. (2012).
Methamphetamine administration targets multiple immune subsets and
induces phenotypic alterations suggestive of immunosuppression. PLoS ONE
7:e49897. doi: 10.1371/journal.pone.0049897
Frontiers in Microbiology | www.frontiersin.org 11 August 2015 | Volume 6 | Article 793
Sriram et al. METH dysregulates T cell responses in chronic viral infection
Hori, S., Nomura, T., and Sakaguchi, S. (2003). Control of regulatory T cell
development by the transcription factor Foxp3. Science 299, 1057–1061. doi:
10.1126/science.1079490
Hu, J. K., Kagari, T., Clingan, J. M., and Matloubian, M. (2011). Expression of
chemokine receptor CXCR3 on T cells affects the balance between effector and
memory CD8 T-cell generation. Proc. Natl. Acad. Sci. U.S.A. 108, E118–E127.
doi: 10.1073/pnas.1101881108
In, S. W., Son, E. W., Rhee, D. K., and Pyo, S. (2005). Methamphetamine
administration produces immunomodulation in mice. J. Toxicol. Environ.
Health Part A 68, 2133–2145. doi: 10.1080/15287390500177156
Jamieson, B. D., Uittenbogaart, C. H., Schmid, I., and Zack, J. A. (1997). High
viral burden and rapid CD4+ cell depletion in human immunodeficiency virus
type 1-infected SCID-hu mice suggest direct viral killing of thymocytes in vivo.
J. Virol. 71, 8245–8253.
Joshi, N. S., and Kaech, S. M. (2008). Effector CD8 T cell development: a balancing
act between memory cell potential and terminal differentiation. J. Immunol.
180, 1309–1315. doi: 10.4049/jimmunol.180.3.1309
Kao, C., Oestreich, K. J., Paley, M. A., Crawford, A., Angelosanto, J. M., Ali,
M. A., et al. (2011). Transcription factor T-bet represses expression of the
inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses
during chronic infection. Nat. Immunol. 12, 663–671. doi: 10.1038/ni.2046
Khanolkar, A., Fuller, M. J., and Zajac, A. J. (2002). T cell responses to viral
infections: lessons from lymphocytic choriomeningitis virus. Immunol. Res. 26,
309–321. doi: 10.1385/IR:26:1-3:309
Kroll, C. M., Zheng, M., and Carr, D. J. (2014). Enhanced resistance of
CXCR3 deficient mice to ocular HSV-1 infection is due to control of
replication in the brain ependyma. J. Neuroimmunol. 276, 219–223. doi:
10.1016/j.jneuroim.2014.08.005
Kung, C. P., Meckes, D. G. Jr., and Raab-Traub, N. (2011). Epstein-Barr virus
LMP1 activates EGFR, STAT3, and ERK through effects on PKCdelta. J. Virol.
85, 4399–4408. doi: 10.1128/JVI.01703-10
Kwack, S. J., Yoon, K. S., Lim, S. K., Gwak, H. M., Kim, J. Y., Um, Y.
M., et al. (2014). A one-generation reproductive toxicity study of 3,4-
methylenedioxy-n-methamphetamine (MDMA, Ecstasy), an amphetamine
derivative, in C57BL/6 mice. J. Toxicol. Environ. Health Part A 77, 1431–1442.
doi: 10.1080/15287394.2014.951759
Loftis, J. M., Choi, D., Hoffman, W., and Huckans, M. S. (2011).
Methamphetamine causes persistent immune dysregulation: a cross-species,
translational report. Neurotox. Res. 20, 59–68. doi: 10.1007/s12640-010-9223-x
Loftis, J. M., and Janowsky, A. (2014). Neuroimmune basis of methamphetamine
toxicity. Int. Rev. Neurobiol. 118, 165–197. doi: 10.1016/B978-0-12-801284-
0.00007-5
Mantri, C. K., Mantri, J. V., Pandhare, J., and Dash, C. (2014). Methamphetamine
inhibits HIV-1 replication in CD4+ T cells by modulating anti-HIV-1 miRNA
expression. Am. J. Pathol. 184, 92–100. doi: 10.1016/j.ajpath.2013.09.011
Martinez, L. R., Mihu, M. R., Gácser, A., Santambrogio, L., and Nosanchuk, J. D.
(2009). Methamphetamine enhances histoplasmosis by immunosuppression of
the host. J. Infect. Dis. 200, 131–141. doi: 10.1086/599328
Marzio, R., Mauël, J., and Betz-Corradin, S. (1999). CD69 and regulation of
the immune function. Immunopharmacol. Immunotoxicol. 21, 565–582. doi:
10.3109/08923979909007126
Mata, M. M., Napier, T. C., Graves, S. M., Mahmood, F., Raeisi, S., and Baum, L.
L. (2015). Methamphetamine decreases CD4 T cell frequency and alters pro-
inflammatory cytokine production in a model of drug abuse. Eur. J. Pharmacol.
752, 26–33. doi: 10.1016/j.ejphar.2015.02.002
Matloubian, M., Concepcion, R. J., and Ahmed, R. (1994). CD4+ T cells are
required to sustain CD8+ cytotoxic T-cell responses during chronic viral
infection. J. Virol. 68, 8056–8063.
Mbanwi, A. N., and Watts, T. H. (2014). Costimulatory TNFR family members in
control of viral infection: outstanding questions. Semin. Immunol. 26, 210–219.
doi: 10.1016/j.smim.2014.05.001
Mendelsohn, J., and Baselga, J. (2006). Epidermal growth factor receptor targeting
in cancer. Semin. Oncol. 33, 369–385. doi: 10.1053/j.seminoncol.2006.04.003
Moser, B., and Loetscher, P. (2001). Lymphocyte traffic control by chemokines.Nat.
Immunol. 2, 123–128. doi: 10.1038/84219
Ng, C. T., Snell, L. M., Brooks, D. G., and Oldstone, M. B. (2013). Networking
at the level of host immunity: immune cell interactions during persistent viral
infections. Cell Host Microbe 13, 652–664. doi: 10.1016/j.chom.2013.05.014
Pal, T., Dutta, S. K., Mandal, S., Saha, B., and Tripathi, A. (2014). Differential
clinical symptoms among acute phase Indian patients revealed significant
association with dengue viral load and serum IFN-gamma level. J. Clin. Virol.
61, 365–370. doi: 10.1016/j.jcv.2014.09.003
Peerzada, H., Gandhi, J. A., Guimaraes, A. J., Nosanchuk, J. D., and Martinez, L. R.
(2013).Methamphetamine administrationmodifies leukocyte proliferation and
cytokine production in murine tissues. Immunobiology 218, 1063–1068. doi:
10.1016/j.imbio.2013.02.001
Penaloza-MacMaster, P., Kamphorst, A. O.,Wieland, A., Araki, K., Iyer, S. S., West,
E. E., et al. (2014). Interplay between regulatory T cells and PD-1 in modulating
T cell exhaustion and viral control during chronic LCMV infection. J. Exp.Med.
211, 1905–1918. doi: 10.1084/jem.20132577
Petrovas, C., Yamamoto, T., Price, D. A., Rao, S. S., Klatt, N. R., Brenchley, J. M.,
et al. (2013). High production rates sustain in vivo levels of PD-1high simian
immunodeficiency virus-specific CD8 T cells in the face of rapid clearance.
J. Virol. 87, 9836–9844. doi: 10.1128/JVI.01001-13
Porichis, F., Kwon, D. S., Zupkosky, J., Tighe, D. P., McMullen, A., Brockman, M.
A., et al. (2011). Responsiveness of HIV-specific CD4 T cells to PD-1 blockade.
Blood 118, 965–974. doi: 10.1182/blood-2010-12-328070
Potula, R., Hawkins, B. J., Cenna, J. M., Fan, S., Dykstra, H., Ramirez, S. H., et al.
(2010). Methamphetamine causes mitrochondrial oxidative damage in human
T lymphocytes leading to functional impairment. J. Immunol. 185, 2867–2876.
doi: 10.4049/jimmunol.0903691
Prasad, K. V., Ao, Z., Yoon, Y., Wu,M. X., Rizk, M., Jacquot, S., et al. (1997). CD27,
a member of the tumor necrosis factor receptor family, induces apoptosis
and binds to Siva, a proapoptotic protein. Proc. Natl. Acad. Sci. U.S.A. 94,
6346–6351. doi: 10.1073/pnas.94.12.6346
Raué, H. P., Beadling, C., Haun, J., and Slifka, M. K. (2013). Cytokine-mediated
programmed proliferation of virus-specific CD8(+) memory T cells. Immunity
38, 131–139. doi: 10.1016/j.immuni.2012.09.019
Reynolds, J. L., Mahajan, S. D., Sykes, D. E., Schwartz, S. A., and Nair, M. P. (2007).
Proteomic analyses of methamphetamine (METH)-induced differential protein
expression by immature dendritic cells (IDC). Biochim. Biophys. Acta 1774,
433–442. doi: 10.1016/j.bbapap.2007.02.001
Riviére, G. J., Gentry, W. B., and Owens, S. M. (2000). Disposition of
methamphetamine and its metabolite amphetamine in brain and other
tissues in rats after intravenous administration. J. Pharmacol. Exp. Ther. 292,
1042–1047.
Shiow, L. R., Rosen, D. B., Brdicková, N., Xu, Y., An, J., Lanier, L. L., et al.
(2006). CD69 acts downstream of interferon-alpha/beta to inhibit S1P1
and lymphocyte egress from lymphoid organs. Nature 440, 540–544. doi:
10.1038/nature04606
Shiratori, Y., Hikiba, Y., Mawet, E., Niwa, Y., Matsumura, M., Kato, N., et al.
(1994).Modulation of KC/gro protein (interleukin-8 related protein in rodents)
release from hepatocytes by biologically active mediators. Biochem. Biophys.
Res. Commun. 203, 1398–1403. doi: 10.1006/bbrc.1994.2340
Steinkellner, T., Freissmuth, M., Sitte, H. H., and Montgomery, T. (2011).
The ugly side of amphetamines: short- and long-term toxicity of 3,4-
methylenedioxymethamphetamine (MDMA, ‘Ecstasy’), methamphetamine
and D-amphetamine. Biol. Chem. 392, 103–115. doi: 10.1515/bc.2011.016
Szabo, S. J., Sullivan, B. M., Peng, S. L., and Glimcher, L. H. (2003). Molecular
mechanisms regulating Th1 immune responses. Annu. Rev. Immunol. 21,
713–758. doi: 10.1146/annurev.immunol.21.120601.140942
Tallóczy, Z., Martinez, J., Joset, D., Ray, Y., Gacser, A., Toussi, S., et al. (2008).
Methamphetamine inhibits antigen processing, presentation, and phagocytosis.
PLoS Pathog. 4:e28. doi: 10.1371/journal.ppat.0040028
Torraca, V., Cui, C., Boland, R., Bebelman, J. P., van der Sar, A.M., Smit, M. J., et al.
(2015). The CXCR3-CXCL11 signaling axis mediates macrophage recruitment
and dissemination of mycobacterial infection. Dis. Model. Mech. 8, 253–269.
doi: 10.1242/dmm.017756
Valencia, F., Bubar, M. J., Milligan, G., Cunningham, K. A., and Bourne,
N. (2012). Influence of methamphetamine on genital herpes simplex virus
type 2 infection in a mouse model. Sex. Transm. Dis. 39, 720–725. doi:
10.1097/OLQ.0b013e31825af129
Volkow, N. D., Fowler, J. S., Wang, G. J., Shumay, E., Telang, F., Thanos, P.
K., et al. (2010). Distribution and pharmacokinetics of methamphetamine
in the human body: clinical implications. PLoS ONE 5:e15269. doi:
10.1371/journal.pone.0015269
Frontiers in Microbiology | www.frontiersin.org 12 August 2015 | Volume 6 | Article 793
Sriram et al. METH dysregulates T cell responses in chronic viral infection
Weller, M. L., Amornphimoltham, P., Schmidt, M., Wilson, P. A., Gutkind, J.
S., and Chiorini, J. A. (2010). Epidermal growth factor receptor is a co-
receptor for adeno-associated virus serotype 6. Nat. Med. 16, 662–664. doi:
10.1038/nm.2145
Welten, S. P., Redeker, A., Franken, K. L., Benedict, C. A., Yagita, H., Wensveen, F.
M., et al. (2013). CD27-CD70 costimulation controls T cell immunity during
acute and persistent cytomegalovirus infection. J. Virol. 87, 6851–6865. doi:
10.1128/JVI.03305-12
Weng, Y., Siciliano, S. J., Waldburger, K. E., Sirotina-Meisher, A., Staruch,
M. J., Daugherty, B. L., et al. (1998). Binding and functional properties of
recombinant and endogenous CXCR3 chemokine receptors. J. Biol. Chem. 273,
18288–18291. doi: 10.1074/jbc.273.29.18288
Wherry, E. J., Blattman, J. N., Murali-Krishna, K., van der Most, R., and Ahmed,
R. (2003). Viral persistence alters CD8 T-cell immunodominance and tissue
distribution and results in distinct stages of functional impairment. J. Virol. 77,
4911–4927. doi: 10.1128/JVI.77.8.4911-4927.2003
Williams, M. A., and Bevan, M. J. (2007). Effector and memory
CTL differentiation. Annu. Rev. Immunol. 25, 171–192. doi:
10.1146/annurev.immunol.25.022106.141548
Wilson, E. B., and Brooks, D. G. (2011). The role of IL-10 in regulating immunity
to persistent viral infections. Curr. Top. Microbiol. Immunol. 350, 39–65. doi:
10.1007/82_2010_96
Yu, Q., Zhang, D., Walston, M., Zhang, J., Liu, Y., and Watson, R. R.
(2002). Chronic methamphetamine exposure alters immune function in
normal and retrovirus-infected mice. Int. Immunopharmacol. 2, 951–962. doi:
10.1016/S1567-5769(02)00047-4
Zheng, K., Kitazato, K., and Wang, Y. (2014). Viruses exploit the function
of epidermal growth factor receptor. Rev. Med. Virol. 24, 274–286. doi:
10.1002/rmv.1796
Zhou, X., Ramachandran, S., Mann, M., and Popkin, D. L. (2012). Role
of lymphocytic choriomeningitis virus (LCMV) in understanding
viral immunology: past, present and future. Viruses 4, 2650–2669. doi:
10.3390/v4112650
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2015 Sriram, Haldar, Cenna, Gofman and Potula. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Microbiology | www.frontiersin.org 13 August 2015 | Volume 6 | Article 793
